Recent findings, including those by our group, support the notable concept that the pharmacological activation of S1P1 or S1P3 improves obesity and associated metabolic disorders, whereas that of S1P2 has the opposite effect. The gene discussed is S1PR3; the disease is obesity due to melanocortin 4 receptor deficiency.